Presurgical medical treatment in Cushing's disease
Paloma Moreno-Moreno(Instituto Maimónides de Investigación Biomédica de Córdoba), Raul Miguel Luque-Huertas, Concepción Muñoz‐Jiménez(Hospital Universitario Reina Sofía), Alejandro Ibáñez‐Costa(Instituto de Salud Carlos III), María Rosa Alhambra-Expósito(Instituto Maimónides de Investigación Biomédica de Córdoba), Ana Barrera-Martín(Instituto Maimónides de Investigación Biomédica de Córdoba), Justo P Castaño-Fuentes, María Ángeles Gálvez-Moreno(Instituto Maimónides de Investigación Biomédica de Córdoba)
Cited by 0
Related Papers
Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas
|Cancer Letters|2015|91
Ghrelin gene products, receptors, and GOAT enzyme: biological and pathophysiological insight
|Journal of Endocrinology|2013|88
A Cellular and Molecular Basis for the Selective Desmopressin-Induced ACTH Release in Cushing Disease Patients: Key Role of AVPR1b Receptor and Potential Therapeutic Implications
|The Journal of Clinical Endocrinology & Metabolism|2013|81
Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro
|Journal of Endocrinology|2016|74
In1-ghrelin splicing variant is overexpressed in pituitary adenomas and increases their aggressive features
|Scientific Reports|2015|60